{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:29:55Z","timestamp":1770143395648,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To evaluate the association between enthesitis resolution (ER) and dactylitis resolution (DR) and meaningful improvements in patient-reported outcomes (PROs) among biologic-na\u00efve patients with PsA receiving guselkumab in the DISCOVER-2 study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Enthesitis and dactylitis, characteristic lesions of PsA, were evaluated by independent assessors using the Leeds Enthesitis Index (range, 0\u20136) and Dactylitis Severity Score (range, 0\u201360). Proportions of patients with ER or DR (score\u2009=\u20090) among those with score\u2009&gt;\u20090 at baseline were determined at weeks 24,\u00a052,\u00a0and\u00a0100. PROs included: fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-Fatigue]), pain (0\u2013100 visual analog scale), physical function (Health Assessment Questionnaire-Disability Index [HAQ-DI]), and health-related quality of life\u00a0(36-item Short-Form Health Survey physical\/mental component summary [SF-36 PCS\/MCS]). Meaningful responses were defined as: improvements of\u2009\u2265\u20094 for FACIT-Fatigue,\u2009\u2265\u20090.35 for HAQ-DI, and\u2009\u2265\u20095 for SF-36 PCS\/MCS and absolute scores of\u2009\u2264\u200915 for minimal pain and\u2009\u2264\u20090.5 for normalized HAQ-DI. Associations between ER\/DR status and PRO response status were tested using a Chi-square test.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Guselkumab-treated patients with ER were more likely than those without ER to achieve minimal pain (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), normalized HAQ-DI (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and PCS response (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) at weeks 24, 52, and 100. Patients with DR were more likely than those without DR to achieve FACIT-Fatigue response at week 24 and week 52 (both <jats:italic>p<\/jats:italic>\u2009\u2264\u20090.01) and minimal pain at week 24 and normalized HAQ-DI at week 52 (both <jats:italic>p<\/jats:italic>\u2009\u2264\u20090.03).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In biologic-na\u00efve patients with active PsA treated with guselkumab, achieving ER or DR was associated with durable improvements in selected PROs, including those of high importance to patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\">https:\/\/clinicaltrials.gov<\/jats:ext-link>) NCT03158285; Registered: May 16, 2017.<\/jats:p>\n                <jats:p><jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td align=\"left\"><jats:bold>Key Points<\/jats:bold><\/jats:td>\n                      <\/jats:tr>\n                      <jats:tr>\n                        <jats:td align=\"left\">\u2022 <jats:italic>At week 100, 65% and 76% of guselkumab-treated patients achieved enthesitis and dactylitis resolution (ER\/DR).<\/jats:italic>\u2022 <jats:italic>Achieving ER was associated with achieving DR and vice versa through the end of study.<\/jats:italic>\u2022 <jats:italic>Achieving ER or DR was associated with durable and meaningful improvements in selected patient-reported outcomes.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-024-06921-8","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:02:37Z","timestamp":1710288157000},"page":"1591-1604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association between enthesitis\/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-2029","authenticated-orcid":false,"given":"Proton","family":"Rahman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-4280","authenticated-orcid":false,"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8740-9615","authenticated-orcid":false,"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Phillip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6005-3938","authenticated-orcid":false,"given":"May","family":"Shawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Cua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2596-2209","authenticated-orcid":false,"given":"Jonathan P.","family":"Sherlock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2059-7866","authenticated-orcid":false,"given":"Alexa P.","family":"Kollmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xie L.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihong","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2602-1219","authenticated-orcid":false,"given":"Christopher T.","family":"Ritchlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7715-8226","authenticated-orcid":false,"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"issue":"10","key":"6921_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376(10):957\u2013970","journal-title":"N Engl J Med"},{"issue":"2","key":"6921_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.semarthrit.2018.02.002","volume":"48","author":"GS Kaeley","year":"2018","unstructured":"Kaeley GS, Eder L, Aydin SZ, Gutierrez M, Bakewell C (2018) Dactylitis: a hallmark of psoriatic arthritis. Semin Arthritis Rheum 48(2):263\u2013273","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"6921_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semarthrit.2017.12.008","volume":"48","author":"GS Kaeley","year":"2018","unstructured":"Kaeley GS, Eder L, Aydin SZ, Gutierrez M, Bakewell C (2018) Enthesitis: a hallmark of psoriatic arthritis. Semin Arthritis Rheum 48(1):35\u201343","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"6921_CR4","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41584-022-00861-w","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB et al (2022) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 18(12):734","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"6921_CR5","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):700\u2013712","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"6921_CR6","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","volume":"13","author":"G Schett","year":"2017","unstructured":"Schett G, Lories RJ, D\u2019Agostino MA, Elewaut D, Kirkham B, Soriano ER et al (2017) Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol 13(12):731\u2013741","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"6921_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41584-018-0147-9","volume":"15","author":"D McGonagle","year":"2019","unstructured":"McGonagle D, Tan AL, Watad A, Helliwell P (2019) Pathophysiology, assessment and treatment of psoriatic dactylitis. Nat Rev Rheumatol 15(2):113\u2013122","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"6921_CR8","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/acr.23249","volume":"69","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Karki C, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT et al (2017) Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the CORRONA Psoriatic Arthritis\/Spondyloarthritis Registry. Arthritis Care Res (Hoboken) 69(11):1692\u20131699","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"6921_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3899\/jrheum.191117","volume":"48","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Liu M, Rebello S, Hua W, McLean RR, Hur P et al (2021) Disease characteristics, quality of life, and work productivity by enthesitis site: real-world data from the US CORRONA Psoriatic Arthritis\/Spondyloarthritis Registry. J Rheumatol 48(3):367\u2013375","journal-title":"J Rheumatol"},{"issue":"1","key":"6921_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40257-015-0169-x","volume":"17","author":"MG Lebwohl","year":"2016","unstructured":"Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS (2016) US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. Am J Clin Dermatol 17(1):87\u201397","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"6921_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105534","volume":"90","author":"JA Walsh","year":"2023","unstructured":"Walsh JA, Ogdie A, Michaud K, Peterson S, Holdsworth EA, Karyekar CS et al (2023) Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: Findings from a real-world study in the United States and Europe. Joint Bone Spine 90(3):105534","journal-title":"Joint Bone Spine"},{"issue":"2","key":"6921_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00296-019-04480-9","volume":"40","author":"I Sunar","year":"2020","unstructured":"Sunar I, Ataman S, Nas K, Kilic E, Sargin B, Kasman SA et al (2020) Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multi-center study. Rheumatol Int 40(2):283\u2013294","journal-title":"Rheumatol Int"},{"issue":"4","key":"6921_CR13","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s40744-020-00242-3","volume":"7","author":"AM Orbai","year":"2020","unstructured":"Orbai AM, Birt JA, Holdsworth EA, Booth N, Malatestinic WN, Sprabery AT et al (2020) Impact of enthesitis on psoriatic arthritis patient-reported outcomes and physician satisfaction with treatment: Data from a multinational patient and physician survey. Rheumatol Ther 7(4):937\u2013948","journal-title":"Rheumatol Ther"},{"issue":"11","key":"6921_CR14","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3899\/jrheum.171406","volume":"45","author":"K Wervers","year":"2018","unstructured":"Wervers K, Luime JJ, Tchetverikov I, Gerards AH, Kok MR, Appels CWY et al (2018) Influence of disease manifestations on health-related quality of life in early psoriatic arthritis. J Rheumatol 45(11):1526\u20131531","journal-title":"J Rheumatol"},{"issue":"10","key":"6921_CR15","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.3899\/jrheum.161459","volume":"44","author":"W Tillett","year":"2017","unstructured":"Tillett W, Dures E, Hewlett S, Helliwell PS, FitzGerald O, Brooke M et al (2017) A multicenter nominal group study to rank outcomes important to patients, and their representation in existing composite outcome measures for psoriatic arthritis. J Rheumatol 44(10):1445\u20131452","journal-title":"J Rheumatol"},{"issue":"11","key":"6921_CR16","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/acr.23174","volume":"69","author":"A Polachek","year":"2017","unstructured":"Polachek A, Li S, Chandran V, Gladman DD (2017) Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: Incidence, prevalence, characteristics, and outcome. Arthritis Care Res (Hoboken) 69(11):1685\u20131691","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10230","key":"6921_CR17","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, Kollmeier AP, Hsia EC, Subramanian RA et al (2020) Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395(10230):1115\u20131125","journal-title":"Lancet"},{"issue":"10230","key":"6921_CR18","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL et al (2020) Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395(10230):1126\u20131136","journal-title":"Lancet"},{"issue":"1","key":"6921_CR19","doi-asserted-by":"publisher","first-page":"e001457","DOI":"10.1136\/rmdopen-2020-001457","volume":"7","author":"CT Ritchlin","year":"2021","unstructured":"Ritchlin CT, Helliwell PS, Boehncke WH, Soriano ER, Hsia EC, Kollmeier AP et al (2021) Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naive or TNF\u03b1 inhibitor-experienced. RMD Open 7(1):e001457","journal-title":"RMD Open"},{"issue":"4","key":"6921_CR20","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/art.41553","volume":"73","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Chakravarty SD et al (2021) Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis. Arthritis Rheumatol 73(4):604\u2013616","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"6921_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Xu XL et al (2022) Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: Results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol 74(3):475\u2013485","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"6921_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/acr2.11537","volume":"5","author":"D McGonagle","year":"2023","unstructured":"McGonagle D, McInnes IB, Deodhar A, Schett G, Shawi M, Chakravarty SD et al (2023) Guselkumab, a selective interleukin-23 p19 subunit inhibitor, resolves dactylitis in patients with active psoriatic arthritis: Pooled results through week 52 from two phase 3 studies. ACR Open Rheumatol 5(4):227\u2013240","journal-title":"ACR Open Rheumatol"},{"issue":"11","key":"6921_CR23","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1093\/rheumatology\/keab285","volume":"60","author":"D McGonagle","year":"2021","unstructured":"McGonagle D, McInnes IB, Deodhar A, Schett G, Shawi M, Kafka S et al (2021) Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. Rheumatology (Oxford) 60(11):5337\u20135350","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"6921_CR24","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy PJ, Helliwell PS (2008) Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 59(5):686\u2013691","journal-title":"Arthritis Rheum"},{"issue":"4","key":"6921_CR25","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"CE Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U et al (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52(4):1227\u20131236","journal-title":"Arthritis Rheum"},{"issue":"5","key":"6921_CR26","first-page":"811","volume":"32","author":"D Cella","year":"2005","unstructured":"Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J (2005) Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 32(5):811\u2013819","journal-title":"J Rheumatol"},{"issue":"7","key":"6921_CR27","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/acr.20155","volume":"62","author":"LC Coates","year":"2010","unstructured":"Coates LC, Helliwell PS (2010) Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 62(7):965\u2013969","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"6921_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23(2):137\u2013145","journal-title":"Arthritis Rheum"},{"issue":"11","key":"6921_CR29","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.3899\/jrheum.110546","volume":"38","author":"PJ Mease","year":"2011","unstructured":"Mease PJ, Woolley JM, Bitman B, Wang BC, Globe DR, Singh A (2011) Minimally important difference of health assessment questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol 38(11):2461\u20132465","journal-title":"J Rheumatol"},{"key":"6921_CR30","doi-asserted-by":"crossref","unstructured":"Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473\u201383","DOI":"10.1097\/00005650-199206000-00002"},{"issue":"2 Suppl 1","key":"6921_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2165\/00019053-200422001-00004","volume":"22","author":"DP Lubeck","year":"2004","unstructured":"Lubeck DP (2004) Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmacoeconomics 22(2 Suppl 1):27\u201338","journal-title":"Pharmacoeconomics"},{"key":"6921_CR32","first-page":"1563","volume":"81","author":"J Curtis","year":"2022","unstructured":"Curtis J, McInnes I, Rahman P, Gladman D, Yang F, Peterson S et al (2022) AB0881 Guselkumab provides sustained improvements in health-related quality of life in patients with active psoriatic arthritis through 2 years of DISCOVER-2. Ann Rheum Dis 81:1563\u20131564","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6921_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13075-021-02554-3","volume":"23","author":"P Rahman","year":"2021","unstructured":"Rahman P, Mease PJ, Helliwell PS, Deodhar A, Gossec L, Kavanaugh A et al (2021) Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis. Arthritis Res Ther 23(1):190","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"6921_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/ard.2007.080952","volume":"67","author":"D McGonagle","year":"2008","unstructured":"McGonagle D, Tan AL, Benjamin M (2008) The biomechanical link between skin and joint disease in psoriasis and psoriatic arthritis: what every dermatologist needs to know. Ann Rheum Dis 67(1):1\u20134","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"6921_CR35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jbspin.2015.07.017","volume":"83","author":"T Gudu","year":"2016","unstructured":"Gudu T, Etcheto A, de Wit M, Heiberg T, Maccarone M, Balanescu A et al (2016) Fatigue in psoriatic arthritis - a cross-sectional study of 246 patients from 13 countries. Joint Bone Spine 83(4):439\u2013443","journal-title":"Joint Bone Spine"},{"issue":"3","key":"6921_CR36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5114\/reum.2017.68911","volume":"55","author":"M Krajewska-Wlodarczyk","year":"2017","unstructured":"Krajewska-Wlodarczyk M, Owczarczyk-Saczonek A, Placek W (2017) Fatigue - an underestimated symptom in psoriatic arthritis. Reumatologia 55(3):125\u2013130","journal-title":"Reumatologia"},{"issue":"1","key":"6921_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3899\/jrheum.180797","volume":"47","author":"A Mourad","year":"2020","unstructured":"Mourad A, Gniadecki R (2020) Treatment of dactylitis and enthesitis in psoriatic arthritis with biologic agents: A systematic review and metaanalysis. J Rheumatol 47(1):59\u201365","journal-title":"J Rheumatol"},{"issue":"1","key":"6921_CR38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1136\/annrheumdis-2014-205839","volume":"74","author":"AL Tan","year":"2015","unstructured":"Tan AL, Fukuba E, Halliday NA, Tanner SF, Emery P, McGonagle D (2015) High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis. Ann Rheum Dis 74(1):185\u2013189","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6921_CR39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1136\/annrheumdis-2014-205461","volume":"75","author":"M Haroon","year":"2016","unstructured":"Haroon M, Winchester R, Giles JT, Heffernan E, FitzGerald O (2016) Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Ann Rheum Dis 75(1):155\u2013162","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"6921_CR40","doi-asserted-by":"publisher","first-page":"e001217","DOI":"10.1136\/rmdopen-2020-001217","volume":"6","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Gladman DD, Deodhar A, McGonagle DG, Nash P, Boehncke WH et al (2020) Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. RMD Open. 6(2):e001217","journal-title":"RMD Open."},{"issue":"9","key":"6921_CR41","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.clinthera.2023.05.010","volume":"45","author":"G Ayan","year":"2023","unstructured":"Ayan G, Ribeiro A, Macit B, Proft F (2023) Pharmacologic treatment strategies in psoriatic arthritis. Clin Ther 45(9):826\u2013840","journal-title":"Clin Ther"},{"issue":"3","key":"6921_CR42","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3899\/jrheum.130949","volume":"41","author":"L Eder","year":"2014","unstructured":"Eder L, Jayakar J, Thavaneswaran A, Haddad A, Chandran V, Salonen D et al (2014) Is the MAdrid Sonographic Enthesitis Index useful for differentiating psoriatic arthritis from psoriasis alone and healthy controls? J Rheumatol 41(3):466\u2013472","journal-title":"J Rheumatol"},{"key":"6921_CR43","doi-asserted-by":"crossref","unstructured":"Ritchlin C, Mease P, Boehncke W, Tesser J, Chakravarty S, Rampakakis E et al (2022) Stringent disease activity control at 2 years across psoriatic arthritis domains irrespective of baseline characteristics in patients treated with guselkumab: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study [abstract]. Arthritis Rheumatol 74(suppl 9). https:\/\/acrabstracts.org\/abstract\/stringent-disease-activity-control-at-2-years-across-psoriatic-arthritis-domains-irrespective-of-baseline-characteristics-in-patients-treated-with-guselkumab-post-hoc-analysis-of-a-phase-3-randomize\/. Accessed\u00a014 Nov 2023","DOI":"10.1136\/annrheumdis-2023-eular.3238"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06921-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-06921-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06921-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T06:03:37Z","timestamp":1713161017000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-06921-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["6921"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-06921-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"assertion":[{"value":"4 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practices; the study protocols were approved by an Institutional Review Board or Ethics Committee at each site, and all patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"<b>PR<\/b> has received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; meeting attendance\/travel support from Janssen; and research grants from Janssen and Novartis. <b>IBM<\/b> has received consultant fees from AbbVie, Amgen, Astra Zeneca, Bristol Myers Squibb, Cabaletta, Compugen, Eli Lilly, Gilead, Glaxo Smith Kline, Janssen, Novartis, Pfizer, Roche, Sanofi, and UCB; grant\/research support from Amgen, Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo Smith Kline, Janssen, Novartis, Roche, and UCB; is a shareholder for Causeway Therapeutics, and Evelo Compugen; NHS GGC Board Member; Evelo Board of Directors; and Versus Arthritis Trustee. <b>AD<\/b> has received consulting fees for participation in Advisory Boards from AbbVie, Amgen, Aurinia, Bristol Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, MoonLake, Novartis, Pfizer, and UCB; Research Grant funding from AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, and UCB; and Speaker fees from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. <b>GS<\/b> has received speaker fees from AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, and Novartis. <b>PJM<\/b> has received research grants from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, SUN Pharma, and UCB; consulting fees from AbbVie, Acelyrin, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Immagene, Janssen, Moonlake Pharma, Novartis, Pfizer, SUN Pharma, UCB, Ventyx, and Xinthera; and speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. <b>MS<\/b>, <b>DJC, JPS, APK, XLX, SS<\/b> are all employees of Janssen (a subsidiary of Johnson & Johnson) and own Johnson & Johnson stock and\/or stock options. <b>CTR<\/b> has received research support from AbbVie, Amgen, and UCB; consultant fees from AbbVie, Amgen, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB. <b>DM<\/b> has received grants\/research support: AbbVie, Celgene, Janssen, Merck, Pfizer, Novartis; receipt of honoraria or consultation fees: AbbVie, Celgene, Janssen, Merck, Novartis, Pfizer, UCB; participation in speaker\u2019s bureau: AbbVie, Celgene, Janssen, Merck, Novartis, Pfizer, UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}